ArticleFrontiers in dental medicine2025
Changes in vertical skeletal and neuromuscular balance in growing patients treated with AMCOP®: a cephalometric and EMG evaluation.
Article in Frontiers in dental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: To evaluate changes in vertical skeletal dimensions and neuromuscular balance in growing patients treated with AMCOP® elastodontic appliances, by comparing pre- and post-treatment cephalometric values (Deltadent®) and standardized surface EMG indices. Materials and methods: This monocentric retrospective case series included 9 consecutive children in deciduous/early mixed dentition treated with AMCOP® according to a staged protocol (Open phase for vertical control, then class-specific device when indicated). Wear was prescribed 1 h/day plus nocturnal use. Lateral cephalograms were traced in Deltadent® at baseline (T0) and after therapy (T1). Primary outcomes were overbite and vertical divergence (SN-GoGn; PP-MP). Secondary outcomes included ANS-Me, overjet, interincisal angle, U1-PP and L1-MP. Neuromuscular balance was assessed with Teethan® (POC TA/MM, BAR, TORS, IMP, ASIM), recorded per SENIAM recommendations. Reliability was checked with ICC and Dahlberg's error; paired comparisons used standard parametric/non-parametric tests ( Results: Treatment was completed without adverse events (median duration ≈12-16 months). Most patients showed closure or reduction of anterior open bite, decreased or well-controlled vertical divergence, increased interincisal angle, and reduced overjet, with upper incisor uprighting and stable lower incisor inclination. sEMG demonstrated consistent improvement: barycenter (BAR) shifted toward the normative zone, torsion/asymmetry indices decreased, and global efficiency (IMP) increased. Conclusions: In growing patients, AMCOP® therapy was associated with favorable vertical control and measurable neuromuscular rebalancing, documented by objective cephalometric and EMG metrics. Prospective controlled studies are warranted to confirm efficacy and long-term stability.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.